Literature DB >> 15928917

Exploring 3D-QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists+.

Prosenjit Bhattacharya1, J Thomas Leonard, Kunal Roy.   

Abstract

Binding affinity data [Bioorg Med Chem (2004) 12:613-623] of thiazole and thiadiazole derivatives (n = 30) for the human adenosine A3 receptor subtype have been subjected to 3D-QSAR (Quantitative structure-activity relationships) analyses by molecular shape analysis (MSA) and molecular field analysis (MFA) techniques using Cerius2 Version 4.8. In the case of the MSA, the major steps were (1) generation of conformers and energy minimization; (2) hypothesizing an active conformer (global minimum of the most active compound); (3) selecting a candidate shape-reference compound (based on the active conformation); (4) performing pairwise molecular superimposition using the maximum common subgroup (MCSG) method; (5) measuring molecular shape commonality using MSA descriptors; (6) determining other molecular features by calculating spatial, electronic and conformational parameters; (7) selection of conformers; (8) generation of QSAR equations by genetic function algorithm (GFA) or stepwise regression. The best 3D-QSAR equation (MSA) obtained from GFA technique shows 70.0% predicted variance (leave-one-out) and 77.7% explained variance. This equation shows the importance of Jurs descriptors (atomic charge weighted positive surface area, relative negative charge and relative positive charge surface area), partial moment of inertia, energy of the most stable conformer and the ratio of common overlap steric volume to volume of individual molecules. In the case of stepwise regression, the best relation showed 46.1% predicted variance and 72.3% explained variance. In the case of MFA, the major steps were (1) generating conformers and energy minimization; (2) matching atoms using a maximum common substructure (MCS) search and aligning molecules using the default options; (3) setting MFA preferences (rectangular grid with 2 A step size, charges by the Gasteiger algorithm, H+ and CH3 as probes); (4) creating the field; (5) analysis by the Genetic partial least squares (G/PLS) method. The equation obtained was of excellent statistical quality: 96.1% explained variance and 71.6% predicted variance. Statistically reliable 3D-QSAR models obtained from this study suggest that these techniques could be useful to design potent A3 receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15928917     DOI: 10.1007/s00894-005-0273-6

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  9 in total

1.  CoMFA-based comparison of two models of binding site on adenosine A1 receptor.

Authors:  I Doytchinova
Journal:  J Comput Aided Mol Des       Date:  2001-01       Impact factor: 3.686

2.  Electronic structure of some adenosine receptor antagonists. VQSAR Investigation.

Authors:  Sabry El-Taher; K M El-Sawy; Rifaat Hilal
Journal:  J Chem Inf Comput Sci       Date:  2002 Mar-Apr

3.  Structure-activity relationships of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists.

Authors:  Kwan-Young Jung; Soo-Kyung Kim; Zhan-Guo Gao; Ariel S Gross; Neli Melman; Kenneth A Jacobson; Yong-Chul Kim
Journal:  Bioorg Med Chem       Date:  2004-02-01       Impact factor: 3.641

4.  Identification and characterization of a cell-surface receptor, P2Y15, for AMP and adenosine.

Authors:  Hisayo Inbe; Shinichi Watanabe; Miwa Miyawaki; Eri Tanabe; Jeffrey A Encinas
Journal:  J Biol Chem       Date:  2004-03-04       Impact factor: 5.157

5.  Exploring QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists using FA and GFA techniques.

Authors:  Prosenjit Bhattacharya; J Thomas Leonard; Kunal Roy
Journal:  Bioorg Med Chem       Date:  2005-02-15       Impact factor: 3.641

6.  Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies.

Authors:  Y Fan; L M Shi; K W Kohn; Y Pommier; J N Weinstein
Journal:  J Med Chem       Date:  2001-09-27       Impact factor: 7.446

7.  QSAR of adenosine receptor antagonists. Part 3: Exploring physicochemical requirements for selective binding of 1,2,4-triazolo[5,1-i]purine derivatives with human adenosine A3 receptor subtype.

Authors:  Kunal Roy; J Thomas Leonard; Chandana Sengupta
Journal:  Bioorg Med Chem Lett       Date:  2004-07-16       Impact factor: 2.823

8.  Novel approaches for modeling of the A1 adenosine receptor and its agonist binding site.

Authors:  Hugo Gutiérrez-de-Terán; Nuria B Centeno; Manuel Pastor; Ferran Sanz
Journal:  Proteins       Date:  2004-03-01

9.  A1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in mice.

Authors:  H Thomas Lee; George Gallos; Samih H Nasr; Charles W Emala
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

  9 in total
  3 in total

1.  Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands.

Authors:  Stefano Costanzi; Irina G Tikhonova; T Kendall Harden; Kenneth A Jacobson
Journal:  J Comput Aided Mol Des       Date:  2008-05-16       Impact factor: 3.686

Review 2.  A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.

Authors:  Kenneth A Jacobson; Stefania Merighi; Katia Varani; Pier Andrea Borea; Stefania Baraldi; Mojgan Aghazadeh Tabrizi; Romeo Romagnoli; Pier Giovanni Baraldi; Antonella Ciancetta; Dilip K Tosh; Zhan-Guo Gao; Stefania Gessi
Journal:  Med Res Rev       Date:  2017-07-06       Impact factor: 12.944

3.  QSAR for RNases and theoretic-experimental study of molecular diversity on peptide mass fingerprints of a new Leishmania infantum protein.

Authors:  Humberto González-Díaz; María A Dea-Ayuela; Lázaro G Pérez-Montoto; Francisco J Prado-Prado; Guillermín Agüero-Chapín; Francisco Bolas-Fernández; Roberto I Vazquez-Padrón; Florencio M Ubeira
Journal:  Mol Divers       Date:  2009-07-04       Impact factor: 2.943

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.